Apr 25, 2019
The Worldwide Market for Anemia Treatment Drugs to 2026 - The Overall Competitive Scenario is Expected to Observe a Paradigm Shift Towards Gene Therapy & Monoclonal Antibody Therapies
Jun 10, 2018
Cellenkos(TM), Inc. Announces FDA Clearance of Investigational New Drug Application for CK0801 for Bone Marrow Failure Syndromes
May 30, 2018
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
Feb 23, 2018
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease
Jan 04, 2018
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Nov 03, 2017
Global Bone Marrow Transplant Market to 2025 by Transplant Type, Disease Indication, End-User & Geography
Oct 24, 2017
Neovii Announces Publication in Journal of Clinical Oncology Demonstrating Grafalon® Reduces Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation
Oct 18, 2017
Novartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
Aug 21, 2017
Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
Jun 26, 2017
Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon® (Anti-Human-T-Lymphocyte Immunoglobulin) as Standard Therapy